• Par oncojornal02 dans Accueil le 5 Juin 2020 à 16:25

    Oncotarget From Wikipedia

     
    June 05, 2020

    Oncotarget

    From Wikipedia, the free encyclopedia
     
     
    Jump to navigationJump to search
    Oncotarget  
    Language English
    Edited by Mikhail Blagosklonny, Andrei V. Gudkov
    Publication details
    History 2010-present
    Publisher
    Frequency Weekly
    Yes
    License Creative Commons Attribution 3.0 License
    Standard abbreviations
    ISO 4 Oncotarget
    Indexing
    ISSN 1949-2553
    OCLC no. 408119940
    Links

    Oncotarget is a twice weekly peer-reviewed open access bio-medical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology. The journal was established in 2010 and is published by Impact Journals. The editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov.

    In 2017, the journal was dropped from MEDLINE.[1][2] In 2018 Clarivate Analytics, who maintain the most prominent Impact factor index, delisted the journal from the Journal Citation Reports and all of its other products because "the journal no longer meets the standards necessary for continued coverage",[3] despite having listed the journal as a "Rising Star from Essential Science Indicators"[4] only a few months prior.[5]

    Abstracting and indexing[edit]

    The journal is abstracted and indexed in PubMed[6], Meta,[7][8][9] and Scopus.[10] It was dropped from Index Medicus/MEDLINE[1][2][6] in 2017 and in 2018 from BIOSIS Previews and the Science Citation Index Expanded.[3]

    Reception[edit]

    The peer review process employed by the journal has been criticized by Jeffrey Beall,[11] a university librarian and expert on predatory open access publishing, who also included the journal on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015.[11][12] Allegedly, journal editor Mikhail Blagosklonny responded by threatening to retract the papers of Beall's colleagues at the University of Colorado.[1][2]

     

    References[edit]

    1. ^ Jump up to:a b c "Widely used U.S. government database delists cancer journal". Retraction Watch. October 25, 2017. Retrieved October 25, 2017. 
    2. ^ Jump up to:a b c Zimmer, Katarina (October 26, 2017). "Oncotarget Journal Cut from Medline". The Scientist. 
    3. ^ Jump up to:a b "Indexing company praises cancer journal, then kicks it out". Retraction Watch. 2018-01-19. Retrieved 2018-01-20. 
    4. ^ "Rising Stars from Essential Science Indicators". Clarivate Analytics. 2017-10-18. Retrieved 2018-01-21. 
    5. ^ "Indexing company praises cancer journal, then kicks it out". Retraction Watch. 2018-01-19. Retrieved 2018-01-21. 
    6. ^ Jump up to:a b "Oncotarget". NLM Catalog. National Center for Biotechnology Information. Retrieved 2016-04-19. 
    7. ^ "Oncotarget | In The News - Press Releases". Retrieved 2018-03-15. 
    8. ^ "When a journal is delisted, authors pay a price". Retraction Watch. 2018-03-06. Retrieved 2018-03-15. 
    9. ^ Oncotarget. "Oncotarget to be Indexed in Highly Esteemed Meta Database". www.prnewswire.com. Retrieved 2018-03-15. 
    10. ^ "Source details: Oncotarget". Scopus preview. Elsevier. Retrieved 2018-01-27. 
    11. ^ Jump up to:a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. WordPress.com. Archived from the original on 20 April 2016. Retrieved 19 April2016. 
      "Oncotarget's Peer Review is Highly Questionable (Jeffrey Beall". KSCIEN (Reprint of Beall's blog post). Retrieved 27 Dec2019. 
    12. ^ Beall, Jeffrey (16 April 2016). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. WordPress.com. Archived from the original on 2 December 2016. Retrieved 19 April 2016. 

    External links[edit]


    When people discuss today’s medicine, accuracy plays one of the most important roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are required to comply with the highest standards. The challenge nowadays is that any conclusions of researches can be posted online and used as a reference without being properly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The major principle of this journal is based on Altmetric scores that are used as a quality indicator. That assists both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a full publications list with corresponding scores above 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the required assistance to anyone, who has interest in oncology.
    “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This paper was released back in 2018 by Oncotarget and completed by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
    The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was utilized for citations in various news articles 69 times. Besides that, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
    Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a short overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is happy to have the ability to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.

    votre commentaire

  • Par oncojornal02 dans Accueil le 5 Juin 2020 à 15:36

    A novel DNA damage response mediated by DNA mismatch repair in Caenorhabditis elegans: induction of programmed autophagic cell death in non-dividing cells

     
    June 05, 2020

    A novel DNA damage response mediated by DNA mismatch repair in Caenorhabditis elegans: induction of programmed autophagic cell death in non-dividing cells




    https://player.fm/podcasts/open-access

    ABSTRACT

    DNA mismatch repair (MMR) contributes to genome integrity by correcting errors of DNA polymerase and inducing cell death in response to DNA damage. Dysfunction of MMR results in increased mutation frequency and cancer risk. Clinical researches revealed that MMR abnormalities induce cancers of non-dividing tissues, such as kidney and liver. However, how MMR suppresses cancer in non-dividing tissues is not understood.

    To address that mechanism, we analyzed the roles of MMR in non-dividing cells using Caenorhabditis elegans (C. elegans), in which all somatic cells are non-dividing in the adult stage. In this study, we used stable MMR-mutant lines with a balancer chromosome. First, we confirmed that deficiency of MMR leads to resistance to various mutagens in C. elegans dividing cells. Next, we performed drug resistance assays, and found that MMR-deficient adult worms were resistant to SN1-type alkylating and oxidizing agents. In addition, dead cell staining and reporter assays of an autophagy-related gene demonstrated that the cell death was autophagic cell death. Interestingly, this autophagic cell death was not suppressed by caffeine, implying that MMR induces death of non-dividing cells in an atl-1-independent manner. Hence, we propose the hypothesis that MMR prevents cancers in non-dividing tissues by directly inducing cell death.


    When people speak of contemporary medicine, accuracy plays one of the most significant roles and human lives are directly dependent on it. Hence, any researches related to medicine are required to meet the top standards. The problem nowadays is that any recommendations of researches can be posted online and used as a reference without being thoroughly verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and tried to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality indicator. That allows both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores above 100 as well as reports discussed previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the required help to anyone, who has interest in oncology.
    “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was released back in 2018 by Oncotarget and completed by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
    The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was used for citations in different news articles 69 times. In addition, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
    Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a short overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is proud to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.

    votre commentaire

  • Par oncojornal02 dans Accueil le 5 Juin 2020 à 15:36

    The story behind Oncotarget

     
    June 05, 2020

    The story behind Oncotarget? A bibliometric analysis

    Abstract

    Being the most proliferative journal of oncology a cancer research of the past decade, the Open Access journal Oncotarget had reached more than 20,000 publications and a relatively high impact factor score in the past years. In 2018, the journal citation report decided to withdraw the status of an impact factor journal. Since there was a large discussion in the scientific community and specific reasons for the withdrawal were not stated, this bibliometric analysis was performed to assess if Oncotarget exhibits any differences in its bibliometric structure compared to other journals. For this purpose, we used the “New Quality and Quantity Indices in Sciences” platform and analyzed 20,000 Oncotarget articles. Density equalizing mapping technique helps to construct maps of cancer research in Oncotarget and shows that it has led to a unique global landscape which is not asymmetrically dominated by the Western hemisphere but exhibits a publishing architecture with a pronounced emphasis on Chinese articles. https://link.springer.com/article/10.1007/s11192-018-2949-6

    When people speak of contemporary medicine, accuracy plays one of the most significant roles and human lives are directly dependent on it. Hence, any researches related to medicine are required to meet the top standards. The problem nowadays is that any recommendations of researches can be posted online and used as a reference without being thoroughly verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and tried to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality indicator. That allows both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores above 100 as well as reports discussed previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the required help to anyone, who has interest in oncology.
    “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was released back in 2018 by Oncotarget and completed by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
    The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was used for citations in different news articles 69 times. In addition, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
    Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a short overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is proud to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
    https://www.nature.com/articles/cddis2014520
     

     


    votre commentaire

  • Par oncojornal02 dans Accueil le 5 Juin 2020 à 15:30

    The Carboxy Terminus of Prospero Regulates Its Subcellular Localization

     
    June 05, 2020

    The Carboxy Terminus of Prospero Regulates Its Subcellular Localization

     Xiaolin Bi, Andrey V. Kajava, Tamara Jones, Zoya N. Demidenko, Mark A. Mortin
     
    DOI: 10.1128/MCB.23.3.1014-1024.2003
     

    ABSTRACT

    Subcellular localization of the transcription factor Prospero is dynamic. For example, the protein is cytoplasmic in neuroblasts, nuclear in sheath cells, and degraded in newly formed neurons. The carboxy terminus of Prospero, including the homeodomain and Prospero domain, plays roles in regulating these changes. The homeodomain has two distinct subdomains, which exclude proteins from the nucleus, while the intact homeo/Prospero domain masks this effect. One subdomain is an Exportin-dependent nuclear export signal requiring three conserved hydrophobic residues, which models onto helix 1. Another, including helices 2 and 3, requires proteasome activity to degrade nuclear protein. Finally, the Prospero domain is missing in prosI13 embryos, thus unmasking nuclear exclusion, resulting in constitutively cytoplasmic protein. Multiple processes direct Prospero regulation of cell fate in embryonic nervous system development.

    The prospero (pros) locus was originally identified and cloned because of its expression in and effects on the developing Drosophila nervous system (9, 28, 36). Prospero contains a DNA-binding homeodomain (5, 28, 36) and was proposed to act as a transcription factor because pros mutations alter the expression of other genes normally expressed in the developing nervous system. The carboxy-terminal 236 amino acids of Prospero (amino acids 1172 to 1407), which include the homeodomain, the Prospero domain, and additional residues amino terminal to the homeodomain, was shown to bind a specific DNA sequence (14) and activate the transcription of reporter genes in transiently transfected tissue culture cells (7, 14).

    Prospero is first detected in the nervous system stem cells or neuroblasts, where it is uniformly cytoplasmic. Before cell division, Prospero relocates to the basal cortex, where it is tethered by attaching to the adapter protein, Miranda (18, 32). A neuroblast divides asymmetrically to regenerate a neuroblast and produce a ganglion mother cell, partitioning all of the Prospero protein to the ganglion mother cell, where it translocates into the nucleus and functions as a transcription factor (16, 33). The ganglion mother cell, which is now committed to differentiate, divides once more to generate two postmitotic neuronal and/or glial cells. In neurons, Prospero is degraded to undetectable levels (36).

    There is a direct correlation between Prospero protein and cell fates during patterning of the Drosophila nervous system. For example, Prospero is a critical regulator of the switch from proliferation of neuroblasts to differentiation of ganglion mother cells. In embryos lacking the pros locus, neuroectodermal cells undergo ectopic cell divisions. In contrast, overexpression of Prospero blocks cell division (26). Another example is the external sense organ precursor cell lineage, where the decision to be a IIa or IIb cell depends on the presence of Prospero protein in the latter (27, 31). Furthermore, when IIb cells produce neuronal and sheath daughter cells, Prospero is degraded in the neurons but not the sheath cells (27). https://mcb.asm.org/content/23/3/1014.full

     
     

    When people discuss today’s medicine, precision plays one of the most important roles and human lives are literally dependent on it. Hence, any researches pertaining to medicine are required to comply with the highest standards. The challenge today is that any conclusions of researches can be shared online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and decided to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores above 100 as well as reports mentioned above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the necessary assistance to anybody, who has interest in oncology.
    “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was released back in 2018 by Oncotarget and written by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
    The publication has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are willing to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Hence, the article about melanoma, was used for citations in various news articles 69 times. In addition, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
    Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is glad to have the chance to share with online customers this highly appreciated and top-quality information, that is trustworthy and reliable.

    votre commentaire

  • Par oncojornal02 dans Accueil le 5 Juin 2020 à 15:26

    Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin

     
    June 05, 2020

    Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin

    Abstract

    Background

    Depending on cellular context, p53-inducing agents (such as nutlin-3a) cause different outcomes including reversible quiescence and irreversible senescence. Inhibition of mTOR shifts the balance from senescence to quiescence. In cell lines with incomplete responses to p53, this shift may be difficult to document because of a high proportion of proliferating cells contaminating arrested (quiescent and senescent) cells. This problem also complicates the study of senescence caused by minimal levels of p21 that are capable to arrest a few cells.

    Methodology

    During induction of senescence by low levels of endogenous p53 and ectopic p21, cells were co-treated with nocodazole, which eliminated proliferating cells. As a result, only senescent and quiescent cells remained.

    Results and Discussion

    This approach revealed that rapamycin efficiently converted nutlin-induced-senescence into quiescence. In the presence of rapamycin, nutlin-arrested MCF-7 cells retained the proliferative potential and small/lean morphology. Using this approach, we also unmasked senescence in cells arrested by low levels of ectopic p21, capable to arrest only a small proportion of HT1080-p21-9 cells. When p21 did cause arrest, mTOR caused senescent phenotype. Rapamycin and high concentrations of nutlin-3a, which inhibit the mTOR pathway in these particular cells, suppressed senescence, ensuring quiescence instead. Thus, p21 causes senescence passively, just by causing arrest, while still active mTOR drives senescent phenotype.

    When public speak of contemporary medicine, accuracy plays one of the most significant roles and people’s lives are directly dependent on it. Hence, any researches pertaining to medicine are required to comply with the top standards. The challenge today is that any outcomes of researches can be posted online and used as a reference without being properly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and tried to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality measure. That assists both readers and authors to verify publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication.” Oncotarget website provides a complete publications list with corresponding scores above 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the required assistance to anybody, who has interest in oncology.
    “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and completed by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
    The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to comprehend the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was utilized for citations in various news articles 69 times. Besides that, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
    Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This article has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get helpful scientific facts. Oncotarget is happy to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
    Blagosklonny
     

     


    votre commentaire